Join
Live feed
·
PRReleasevia Quantisnow
Inhibrx Biosciences Inc. logo

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

ByQuantisnow·Wall Street's wire, on your screen.
INBX· Inhibrx Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INBX (Inhibrx Biosciences Inc.) and more on Quantisnow.